Related references
Note: Only part of the references are listed.Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
Erminia Massarelli et al.
JAMA ONCOLOGY (2019)
The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival
Saskia J. Santegoets et al.
CLINICAL CANCER RESEARCH (2019)
Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status
Zeno A. R. Gouw et al.
ORAL ONCOLOGY (2018)
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival
S. J. A. M. Santegoets et al.
ONCOIMMUNOLOGY (2018)
Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2018)
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari et al.
LANCET (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients
Y. Cho et al.
ANNALS OF ONCOLOGY (2016)
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Elham Beyranvand Nejad et al.
CANCER RESEARCH (2016)
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Mariette I. E. van Poelgeest et al.
CLINICAL CANCER RESEARCH (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
Marij J. Welters et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
Ryo Kitagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Tetje C. van der Sluis et al.
CLINICAL CANCER RESEARCH (2015)
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer
Domenica Lorusso et al.
GYNECOLOGIC ONCOLOGY (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
Pia Kvistborg et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial
Eliane C. M. Zeestraten et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Mariette I. E. van Poelgeest et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing
Francesca Spadaro et al.
BLOOD (2012)
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+and CD8+T-cell responses using overlapping peptide pools
Satwinder Kaur Singh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Mark L. Bagarazzi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Marij J. P. Welters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response
Peggy J. de Vos van Steenwijk et al.
CLINICAL CANCER RESEARCH (2008)
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio:: Which variable determines survival of cervical cancer patients?
Ekaterina S. Jordanova et al.
CLINICAL CANCER RESEARCH (2008)
Induction of tumor-specific CD4+ and CD8+ T-Cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillornavirus antigens
Sjoerd H. van der Burg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
High number of intraepithelial CD8(+) tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer
Sytse J. Piersma et al.
CANCER RESEARCH (2007)
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+T-cell immunity against early antigens E2 and E6
A de Jong et al.
CANCER RESEARCH (2004)
Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers
KS Ryu et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2001)
Share Paper
